Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.66 |
| ▸ | CLK3 | P49761 | 17/20 | 0.66 |
| ▸ | CLK2 | P49760 | 17/20 | 0.66 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
| ▸ | WNT1 | P04628 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18444947 | 0.92 | CLK2 (0.65) | DYRK1ACLK3CLK2ITKPIM1 | |
| SCHEMBL20775523 | 0.91 | CLK2 (0.67) | DYRK1ACLK3CLK2ITKWNT1 | |
| SCHEMBL18442440 | 0.90 | CLK3 (0.73) | DYRK1ACLK3CLK2PIM1PIM2 | |
| SCHEMBL18445109 | 0.90 | CLK2 (0.55) | DYRK1ACLK3CLK2ITK | |
| SCHEMBL18444969 | 0.90 | CLK3 (0.76) | DYRK1ACLK3CLK2WNT1TGFBR1 | |
| SCHEMBL18444920 | 0.89 | CLK2 (0.59) | DYRK1ACLK3CLK2ITKWNT1 | |
| SCHEMBL18449201 | 0.89 | CLK2 (0.83) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18450386 | 0.88 | CLK2 (0.70) | DYRK1ACLK3CLK2ITKPIM1 | |
| SCHEMBL18445275 | 0.88 | CLK2 (0.61) | DYRK1ACLK3CLK2ITKWNT1 | |
| SCHEMBL20775560 | 0.87 | CLK2 (0.58) | DYRK1ACLK3CLK2ITKPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | claimed |
| WO-2017023993-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2017023993-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 503/4885CLK3 1498/4885CLK2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.